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Abstract: Beta toxin (CPB) is a small hemolysin beta pore-forming toxin (β-PFT) produced by
Clostridium perfringens type C. It plays a central role in the pathogenesis of necro-hemorrhagic
enteritis in young animals and humans via targeting intestinal endothelial cells. We recently identified
the membrane protein CD31 (PECAM-1) as the receptor for CPB on mouse endothelial cells. We
now assess the role of CD31 in CPB cytotoxicity against human endothelial and monocytic cells
using a CRISPR/Cas9 gene knockout and an antibody blocking approach. CD31 knockout human
endothelial and monocytic cells were resistant to CPB and CPB oligomers only formed in CD31-
expressing cells. CD31 knockout endothelial and monocytic cells could be selectively enriched out of
a polyclonal cell population by exposing them to CPB. Moreover, antibody mediated blocking of the
extracellular Ig6 domain of CD31 abolished CPB cytotoxicity and oligomer formation in endothelial
and monocytic cells. In conclusion, this study confirms the role of CD31 as a receptor of CPB on
human endothelial and monocytic cells. Specific interaction with the CD31 molecule can thus explain
the cell type specificity of CPB observed in vitro and corresponds to in vivo observations in naturally
diseased animals.
Keywords: PECAM-1; CD31; Clostridium perfringens; beta-toxin; pore forming toxin; membrane
receptor; endothelial cell; monocyte; human; CRISPR/Cas9
Key Contribution: Our results define CD31 (PECAM-1) as the membrane receptor for C. perfringens
beta-toxin on human endothelial and monocytic cells.
1. Introduction
Clostridium perfringens beta-toxin (CPB) is a highly potent exotoxin produced by
Clostridium perfringens type C. It is essential for the induction of a fatal acute necro-
hemorrhagic enteritis (NE) in newborn animals, particularly in piglets [1,2]. In humans,
type C enteritis was a significant cause of childhood lethality in the highlands of Papua
New Guinea until a successful vaccination program was implemented [3]. Nowadays,
reports in humans are sporadic [4–7].
CPB is produced as a monomeric protein with a molecular weight of 34.86 kDa [8].
It belongs to the small beta–pore-forming toxins (β-PFT) of the hemolysin family [9].
β-PFTs are secreted as water-soluble monomers that bind to membrane receptors on
their target cells. Surface binding leads to an increase in the local concentration of β-
PFTs, oligomerization and the assembly of a prepore complex that subsequently inserts
into the lipid bilayer and forms a functional transmembrane pore [10–12]. The pores
disturb membrane permeability by allowing the passage of ions leading to intracellular
concentration changes and responses of the affected cells.
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CPB damages the endothelium of mucosal vessels in the small intestine [13–15].
In vitro, the toxicity of CPB is remarkably specific toward endothelial cells, platelets and
different human cell lines of the hematopoietic lineage, such as the monocytic and mye-
locytic THP-1 and U937 cells [15–19]. We recently identified Platelet Endothelial Cell
Adhesion Molecule-1 (CD31 or PECAM-1) as a specific membrane receptor for CPB on
mouse endothelial cells [19]. In addition, we discovered that the extracellular membrane
proximal Ig6 domain of CD31 is essential for the interaction with CPB. Conservation of this
domain between susceptible species, such as mice, humans and pigs, predicts the targeting
of CD31 by CPB in different host species. Because CPB targets other CD31-expressing
cells [19], we additionally wanted to prove the essential function of CD31 in human mono-
cytic cells lines. In the present study, we demonstrate that CD31 functions as the membrane
receptor for CPB on human endothelial and monocytic cell lines using a CRISPR/Cas9 gene
knockout approach and antibody mediated blocking of the Ig6 domain of human CD31.
2. Results and Discussion
2.1. Human Endothelial and Monocytic Cell Lines Express CD31 and Are Susceptible to CPB
For our study, we used the human endothelial cell line HMEC-1, the human endothe-
lial somatic cell hybrid line EA.hy926, the human monocytic leukemia cell line THP-1
and the human monocytic-like cell line U937 (derived from a histiocytic lymphoma). Cell
viability tests confirmed previous results from our and other groups that these cells are
sensitive to the cytotoxic effects of CPB (Figure 1A,C) [17,19–21]. We verified CD31 protein
expression by Western blotting (Figure 1B,D).
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Figure 1. Susceptibility of human endothelial and monocytic cells to CPB. (A) Viability of HMEC-1 
and EA.hy926 incubated with the indicated concentrations of CPB (24 h, 37 °C) as a percentage of 
untreated control cells. Data are represented as means (n = 8) ± SD. (B) Western blots of HMEC-1 
Figure 1. Susceptibility of human endothelial and monocytic cells to CPB. (A) Viability of HMEC-1
and EA.hy926 incubated with the indicated concentrations of CPB (24 h, 37 ◦C) as a percentage of
untreated control cells. Data are represented as means (n = 8)± SD. (B) Western blots of HMEC-1 and
EA.hy926 whole cell lysates showing CD31 protein expression. Tubulin served as a loading control.
(C) Viability of THP1 and U937 incubated with the indicated concentrations of CPB (24 h, 37 ◦C) as
a percentage of untreated control cells. Data are represented as means (n = 8) ± SD. (D) Western
blots of THP-1 and U937 whole cell lysates showing CD31 protein expression. Tubulin served as a
loading control.
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2.2. CD31 Is Essential for CPB-Mediated Cytotoxicity in Human Endothelial and Monocytic Cells
To investigate whether CD31 expression is essential for CPB toxicity in human en-
dothelial and monocytic cell lines, we employed a CRISPR/Cas9 single gene knockout
approach. First, we introduced Cas9 and two independent guide RNAs (gRNAs) targeting
exon 5 and 6 of the CD31 gene named gRNA1 (gR.1) and gRNA2 (gR.2), respectively, into
HMEC-1 cells. After puromycin selection, the resulting polyclonal cell populations were
sequenced and the editing efficiency of each gRNA were compared with cells transduced
with non-targeting gRNA (gR.NT) using TIDE analysis. This showed that the gRNA tar-
geting exon 6 (gR.2) was efficient in generating frameshift mutations in the CD31 gene
(Figure 2A). Next, we transduced all other cell lines using this gRNA. This resulted in
polyclonal cell populations with 79–92% frameshift mutations in the CD31 gene (Figure 2B)
and a substantial decrease in CD31 protein expression levels (Figure 2C). Cell viability tests
with these polyclonal cell populations confirmed that the loss of CD31 expression resulted
in significantly increased resistance to CPB (Figure 2D). Western blotting showed that CPB
oligomer formation depends on the expression of CD31 (Figure 2E). In combination with
the cell viability tests, this clearly indicates that cell damage by CPB depends on CD31
expression in the investigated cell lines.
We rescued EA.hy926∆CD31gR.2 cells with full-length human CD31-GFP (EA.hy926∆CD
31gR.2/CD31), modified by four silent mutations to avoid further editing by Cas9. CD31-
GFP expression restored the susceptibility to CPB (Figure 3A,B). We were however unable
to restore CD31-GFP expression in HMEC-1 and both monocytic cell lines because these
cells stopped proliferating after transductions. We therefore ectopically expressed the same
construct in HEK293FT cells, which lack endogenous CD31. This rendered these cells
susceptible to CPB (Figure 3C,D). In addition, oligomer formation of CPB only occurred in
HEK293huCD31-GFP cells (Figure 3E).




Figure 2. CD31 knockout cells are resistant to CPB. (A) TIDE analysis of HMEC-1∆CD31 gR.1 and gR.2 (B) TIDE analysis 
of CD31gR.2 in HMEC-1, EA.hy926, THP-1 and U937. (C) Western blots of HMEC-1, EA.hy926, THP-1 and 
U937∆CD31gR.2 polyclonal cell populations. As control, cells transduced with gR.NT were used. Tubulin served as load-
ing control. (D) Viability of CD31gR.2 transduced cells incubated with 1 µg/mL or 8 µg/mL CPB (24 h/37 °C) as a percent-
age of untreated control cells. Multiple comparison two-way ANOVA, Sidak’s multiple comparison test, values with p < 
0.0001 are indicated by an asterisk. Data are represented as means (n = 8) ± SD. (E) Western blots of RIPA lysates of HMEC-
1, EA.hy926, THP-1 and U937∆CD31gR.2 polyclonal cell populations incubated with 8 µg/mL CPB (20 min, 37 °C) and 
purified recombinant CPB probed with anti-CPB and anti-CD31 antibodies. Tubulin served as loading control. 55 kDa 
band in THP-1 and U937 panels are remnant of tubulin signal. 
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in THP-1 and U937 panels are remnant of tubulin signal.
2.3. Selective Enrichment of CD31 Knockout Cells with CPB
To further prove the importance of CD31 in susceptibility to CPB, we tested whether
we could select HMEC-1 cells that lost CD31 expression out of a polyclonal cell population.
To this purpose, we incubated HMEC-1 cells targeted with the less efficient gR.1 (9%
frameshift mutations) with a cytotoxic dose of CPB (1 µg/mL for 24 h). After the first
exposure of the CD31gR.1 cells to CPB, a moderate number of surviving cells were observed
after 24 h (Figure 4A). These cells were then grown to confluence, sequenced and TIDE
analysis was performed. Results showed a marked enrichment of cells carrying frameshift
mutations in the CD31 gene from 9% to 79.2% (Figure 4B). These cells were then largely
resistant to a second incubation with the toxin (Figure 4A). This was accompanied by
a loss of CD31 expression in HMEC-1∆CD31gR.1 cells under CPB selection (Figure 4C).
We next repeated the same experiment with THP-1 cells, obtaining very similar results
(Figure 4D–F).
Taken together, our findings highlight the essential role of CD31 in CPB-mediated
cytotoxicity. Using a CRISPR/Cas9 knockout approach, we could confirm our previous
results obtained with CD31 knockout mouse endothelioma cells in human endothelial
cells. Importantly, we could also show the essential role of CD31 for CPB cytotoxicity
in human monocytic cell lines. CD31 is a 130 kDa type 1 transmembrane glycoprotein
that belongs to the Immunoglobulin (Ig)-superfamily of cell adhesion molecules [22]. It
is highly expressed in endothelial cells, where it is a constituent of cell junctions and
concentrated at the lateral cell borders [23,24]. In addition, CD31 is also expressed on
the surface of non-erythroid cells of the hematopoietic lineage (platelets, macrophages,
monocytes, neutrophils, T- and B-Lymphocytes) [23]. In contrast, CD31 is absent from
epithelial cells, fibroblast and red blood cells [25]. Thus, cellular expression of CD31
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overlaps with the in vitro cell type specificity of CPB reported so far [11,17–19,21,26]. This
observation correlates with in vivo findings, where CPB has been shown to target vascular
endothelial cells in the small intestine of affected hosts [13,14]. Although epithelial damage
has been shown to occur rapidly in infection models of C. perfringens type C enteritis [27],
currently there is no clear evidence that CPB directly damages epithelial cells through
pore-formation [28]. As our study concentrated on the role of CD31, we cannot exclude
that CPB can bind to alternative receptors on other cells. Nagahama et al. reported that the
widely expressed membrane molecule P2X7 could function as a CPB receptor on monocytes
and other cells [29]. We therefore investigated the P2X7 expression of all cells used in our
study by Western blotting and found no alterations in P2X7 protein levels that could
account for the different susceptibilities of CD31 proficient and deficient cells (Figure S1).
More detailed studies to determine the potential interaction between CPB and P2X7 would
thus be necessary to explain this discrepancy between our results and those reported by
Nagahama et al. [29].




Figure 3. Reconstitution of CD31 expression restores CPB susceptibility. (A) Western blots of EA.hy926∆gR.NT, 
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EA.hy926∆CD31gR.2 and EA.hy926∆CD31gR.2 cells re-transduced with CD31-GFP (EA.hy926∆CD31gR.2/CD31) probed
with the indicated antibodies. Tubulin served as loading control. (B) Viability of EA.hy926∆gR.NT, EA.hy926∆CD31gR.2
and EA.hy926∆CD31gR./CD31 incubated with indicated concentrations of CPB. Viability data are represented as means
(n = 8) ± SD. Multiple comparison two-way ANOVA, Sidak’s multiple comparison test, values with p < 0.0001 are in-
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(1 µg/mL, 24 h, 37 ◦C) (200×magnification). (E) TIDE analysis of THP-1∆CD31gR.1 before and after selection with CPB. As
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selection with CPB probed with the indicated antibodies. Tubulin served as loading control.
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2.4. Blocking the CD31 Ig6 Domain Protects Sensitive Cells against CPB Induced Cytotoxicity
CD31 is composed of a large extracellular domain containing six Ig-like domains, fol-
lowed by a single pass α-helical transmembrane domain and a cytoplasmic tail of variable
length [30]. The cytoplasmic domain participates in signaling functions. CD31′s adhesive
properties are mediated by its extracellular domain via binding to other CD31 ectodomains
(homophilic adhesion) or other ligands (heterophilic adhesion) [24]. CD31/CD31 ho-
mophilic interactions are mediated by the Ig1 and Ig2 domain [31–34].
They include either cis interactions between adjacent CD31 molecules in the same
membrane or trans interactions between individual CD31 from adjacent cells [34,35]. The
latter are essential for concentrating CD31 at the endothelial cell borders. Here, CD31
contributes to cell junctional integrity and mediates neutrophil diapedesis across the
vascular wall [36]. CD31 also binds to other ligands, including integrin αVβ3 (present
on platelets), CD38 and CD177 (present on leukocytes) via its Ig6 domain [37–39]. The
binding interaction between CD177 on neutrophils and CD31 on endothelial cells has
been shown to be important for CD31-mediated leukocyte transmigration [40]. We had
previously determined that the extracellular Ig6 domain of mouse CD31 is essential for
the interaction of the receptor with CPB, and hypothesized that this domain contains the
binding site for CPB. Chimeric proteins of mouse CD31 containing the human and porcine
CD31 Ig6 domain also interacted with CPB, indicating conservation of the receptor binding
region in these three species [19]. To further consolidate that human CD31 serves as a
membrane receptor for CPB via its Ig6 domain, we now employed a previously described
monoclonal antibody (mAb) blocking approach using three distinct human CD31 mAbs:
one blocking the Ig1 domain (mAb 1.3) and two blocking the Ig6 domain (mAbs 1.2 and
4G6) [33]. EA.hy926 and THP-1 cells pre-incubated with antibodies blocking the CD31 Ig6
domain became resistant to CPB, whereas blocking the CD31 Ig1 domain had no effect on
CPB cytotoxicity (Figure 5A,C,D). Moreover, Ig6 domain blocking abolished the formation
of SDS-resistant oligomers in these cells, demonstrating that pore formation in the plasma
membrane was prevented (Figure 5B,E). The epitope for the mAb4G6 has been localized to
a hexapeptide sequence (CAVNEG) located at AA position 523–528 [41] (signal peptide
included in numbering). Because this sequence is not conserved between humans and mice,
this antibody only blocks human Ig6 function. Importantly, the epitope is located directly
proximal to the region that we previously identified to be essential for CPB interaction
across mouse, human and porcine CD31 Ig6 using mutational studies (Figure S2) [19]. Yan
et al. [41] showed that the 4G6 epitope is at least partially conformation dependent as
antibody binding to this region was influenced by amino acid exchanges in a 15 amino acid
region (CAVNEGSGPITYKFY). The last two amino acids of this region overlap with the
one shown by us to be essential for interacting with CPB [19]. Ig domains consist of seven
to nine antiparallel β-strands arranged into two sheets linked by a disulfide bond [42].
Assuming a similar fold of Ig6 as in the Ig1 and Ig2 domains [31], the entire region now
defined by two independent approaches seems to be important for CPB cytotoxicity and
oligomer formation. This region is located in a surface-exposed loop between two beta
strands of the Ig 6 domain. It is thus accessible for potential binding partners. Binding
of the antibody to this region could inhibit CD31-CPB interaction by directly blocking
the binding site, induction of conformational changes affecting the binding site, or by
steric hindrance. So far, neither the structure of the CD31 Ig6 domain nor that of CPB
have been clearly defined. In addition, we currently do not know whether the monomer
and/or the oligomeric form of CPB bind to the CD31 molecule. Although we were able to
co-immunoprecipitate CPB oligomers with CD31 in our previous study [19], interaction
with the monomer and subsequent oligomerization could be so rapid that we are unable to
detect interaction with monomeric CPB using this method. Determining the structure of
CPB and the CD31 Ig6 domain will be essential to investigate the molecular basis of the
CPB–receptor interaction.
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and Ig6 domain monoclonal antibodies for 1 h/37 ◦C followed by addition of 1 µg/mL CPB for 24 h/37 ◦C. Scale bar,
100 µm. (D) Viability of THP-1 cells pre-incubated with anti-CD31 Ig1 and Ig6 domain monoclonal antibodies for 1 h/37 ◦C
followed by addition of 1 µg/mL CPB for 24 h, 37 ◦C. Data are represented as means (n = 10) ± SD. Multiple comparison
two-way ANOVA, Sidak’s multiple comparison test, values with p < 0.0001 are indicated by an asterisk. (E) Western blots of
THP-1 cells pre-incubated with mAbs as in D, exposed to 8 µg/mL CPB for 60 min at 37 ◦C and probed with anti-CPB and
anti-CD31 antibodies. Tubulin served as loading control. CD31 Ig6 domain mAbs are highlighted in a blue box (1.2) and a
green box (4G6).
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3. Conclusions
This study confirms the essential role of CD31 (PECAM-1) for CPB-mediated cyto-
toxicity in human endothelial and monocytic cells using a CRISPR/Cas9 gene knockout
approach. Using antibody blocking of CD31 extracellular Ig domains, we further substan-
tiate the notion that a particular surface exposed region in the Ig6 membrane proximal
domain plays an essential role in the interaction with CPB. This confirms our previous
results where we could unambiguously show that CD31 is the cell type specific receptor
for CPB on mouse endothelial cells. Extending these results to CD31-expressing monocytic
cells supports the hypothesis, that the specific interaction of the toxin with this membrane
receptor accounts for the remarkable cell type specificity of CPB observed in vitro. The spe-
cific expression of CD31 on endothelial and hematopoietic lineage cells make this molecule
a plausible target for C. perfringens type C. Besides vascular damage and hemorrhage
that produces favorable growth conditions for this bacterium, targeting phagocytes and
potentially other CD31 expressing immune cells could help the pathogen to evade the
immune response of the host.
4. Materials and Methods
4.1. Cells and Reagents
HMEC-1 (ATCC, CRL-3243™) and EA.hy926 (ATCC, CRL-2922™) were cultivated
in MCDB 131 Medium (Gibco, product 10372019) supplemented with 10% fetal bovine
serum FBS (Gibco), 10 ng/mL epidermal growth factor EGF (Gibco), 10 mM L-Glutamine
(Gibco), 1 µg/mL Hydrocortisone (Sigma Aldrich, St. Louis, MO, USA), in the presence
of 1% penicillin-streptomycin (Gibco) grown at 37 ◦C in an atmosphere containing 5%
CO2. HEK293FT cells were cultured in DMEM medium (Gibco, product 41965-039) sup-
plemented with 10% FBS and 1% penicillin-streptomycin. U937 and THP-1 cells (kindly
provided by Dr. René Köffel, Institute of Anatomy, University of Bern, Switzerland) were
grown in RPMI 1640 medium (Gibco, product 11875-093) supplemented with 10% FBS and
1% penicillin-streptomycin.
4.2. Recombinant CPB Production
For cell culture and in vitro experiments, recombinant CPB was designed as N-
terminally His-Tagged protein (Supplementary Table S1) and the codon optimized gene
was ordered from GenScript® (Piscataway, NJ, USA). Recombinant CPB toxin was pro-
duced and purified by the Protein Production and Structure Core Facility of the EPFL
(Lausanne, Switzerland). CPB concentrations were determined using the Pierce™ BCA
protein assay Kit (ThermoFischer Scientific, Waltham, MA, USA) and confirmed by SDS-
PAGE. Activity of each batch was tested prior experiments on primary porcine endothelial
cell cultures as described [43].
4.3. Western Blotting
Cells were washed with PBS and lysed with modified RIPA buffer (25 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1% NP-40, 1% Na-Deoxycholate, 0.1% SDS and complete protease
inhibitor cocktail EDTA-free (Roche, Basel, Switzerland)) for 60 min on ice. Lysates were
cleared using centrifugation (16,000 RCF, 20 min 4 ◦C). Total protein concentration was
determined using the PierceTM BCA protein assay kit (ThermoFischer Scientific) and the
supernatants were adjusted to 2% SDS in reducing gel sample buffer and boiled for 5 min.
Protein samples (40 µg) were separated by 7–10% acrylamide Tris-glycine SDS-PAGE
and transferred onto 0.45 µm nitrocellulose membranes (GE Healthcare). Membranes
were blocked in blocking buffer (Intercept® PBS Blocking Buffer, Li-COR) and incubated
overnight with primary antibodies at 4 ◦C. The monoclonal antibodies used were mouse
anti-CD31 (Santa Cruz, H-3, dilution 1:500), mouse anti-CPB (10A2, USDA, 1:1000) and
mouse anti-α-tubulin (Sigma-Aldrich clone DM1A, dilution 1:5000). The polyclonal anti-
body used was rabbit anti-P2X7 (Almone labs APR-004, 1:300). Antibodies were detected
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with an Azure imaging system (c600) using IRDye secondary antibodies (Li-COR Bio-
sciences, dilution 1:5000).
4.4. SDS-Resistant Oligomer Formation
Cells were incubated with 8 µg/mL CPB for 20 min at 37 ◦C for adherent cells and
10 µg/mL CPB for 60 min at 37 ◦C for suspended cells. Cells were lysed in modified RIPA
buffer as described above, supernatants were adjusted to 2% SDS in reducing gel sample
buffer and boiled for 5 min. Protein samples (100 µg) were separated by 7% acrylamide
Tris-glycine SDS-PAGE and analyzed by Western blotting.
4.5. Cell Viability Assays
Effects of CPB on cells were measured using CellTiter-Blue® (Promega Corporation,
Madison, WI, USA) Cell Viability Assay (Promega #G8080). Cells (30,000 cells/cm2) were
grown to confluency in a 96-well plate and incubated with CPB for 24 h. Resazurin dye
was added to a 0.002% final concentration, incubated for 2 h at 37 ◦C and fluorescent
signal intensity was quantified using the EnSpire Multimode Plate Reader (PerkinElmer,
Waltham, MA, USA) at excitation and emission wavelengths of 540 and 612 nm, respectively.
Viability of cell lines was calculated as percentage of average values determined with
untreated control cells (n = 4) according to the following formula: (Florescence value of the
well)/(average value of 4 control cell wells) × 100.
For visualization of cytopathic effects of adherent endothelial cell lines, cells were
seeded in 96-well plates, grown to confluence and exposed to CPB (1 µg/mL) for 24 h,
fixed with methanol and stained with Eosin/Azur dye (Hemacolor® Rapid staining of
blood smear, Merck KGaA, Darmstadt, Germany). Cytopathic effects were evaluated by
light microscopy with 200×magnification. For THP-1 cells, images of unfixed cells were
taken by light microscopy with 200×magnification.
4.6. Generation of CD31 Knockout Cell Lines
CD31 was knocked out in HMEC-1, EA.hy926, THP-1 and U937 using CRISPR/Cas9
system. We adopted two different gRNA targets for human CD31 gene named CD31 gR.1
(CTTCCATGATCATTCCGGTG) and CD31 gR.2 (ATAGCCTCAAAGTCGGACAG) and a
non-target sequence for negative control (TGATTGGGGGTCGTTCGCCA) from the human
Brunello library [44]. Forward and reverse single-stranded oligonucleotides of each gRNA
were ordered from Microsynth (Balgach, Switzerland) and were annealed to generate
a double-stranded oligonucleotide. These target sequences were cloned into the plenti-
CRISPR v2 (Addgene #52961) which contains sgRNA, Cas9 and a puromycin resistance
cassette. The vector was transformed into Endura chemically competent cells (Lucigen
#60240). Bacteria were grown on LB agar plates with carbenicillin and incubated at 37 ◦C
overnight. Clones were selected and grown in LB broth overnight. Plasmids were purified
and sequenced with the U6 forward primer (GAGGGCCTATTTCCCATGATTCC) to verify
the presence and proper orientation of double-stranded oligonucleotide. HEK293FT cells
were plated at a density of 57,000 cells/cm2 for 24 h prior to transfection in a 150 mm
cell culture dish. Transfection was performed using a calcium phosphate precipitation
protocol. Briefly, we mixed the 32 µg Transfer vector (lentiCRISPR v2 gRNA) with the
following packaging plasmids: 9 µg pCMV-VSVG (Addgene #8454), 12.5 µg pMDLg/pRRE
(Addgene #12251) and 6.25 µg RSV-Rev (Plasmid #12253). The plasmid solution made up
to a final volume of 1125 µL of 0.1× TE/dH2O. 125 µL of 2.5M CaCl2 was added, and the
mixture was incubated at RT for 5 min. After incubation, we added 2× HBS dropwise to
the mix while vortexing at full speed. The transfection mixture was added dropwise to the
cells. The growth medium was refreshed 16 h post transfection. The virus-containing media
were harvested and cleared by filtration through 0.45 µm cellulose acetate filters (GVS
Filter Technology, Sanford, ME, USA) 48 and 72 h post-transfection. Lentivirus containing
media were concentrated by ultracentrifugation at 22 k rpm for 2 h, 4 ◦C. The lentivirus
pellets were resuspended in PBS and stored at −80 ◦C. qPCR Lentivirus Titer Kit (abm #
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LV900) was used to measure the concentration of the viruses using the ABI® 7500 Fast real
time PCR system. For the transduction, cells were seeded at a density of 26,000 cells/cm2
in a six-well plate and cultivated for 24 h. The culture medium was replaced by 4 mL of
8 µg/mL polybrene containing medium and along with lentivirus at a MOI of 10. After
incubation for 48 h, the growth medium was refreshed. For selection of CRISPR-targeted
cells, puromycin (2.5 µg/mL in EA.hy926 and U937 cells, 2 µg/mL in THP-1 cells and
1 µg/mL in HMEC-1 cells) was added 48 h post-transduction and maintained for 3 days.
To determine the efficiency of the integration of each gRNA, the TIDE analysis tool was
used [45]. We isolated gDNA of each cell lines using DNeasy Blood & Tissue Kit (Qiagen
# 69504). gRNA sequences that were integrated into the genomes of the cells were amplified
using primers annealing up- and downstream of the gRNA sequence. The PCR products
were purified using NucleoSpin Gel and PCR Clean-up (Macherey Nagel # 740609) and
sequenced in Microsynth (Balgach, Switzerland).
4.7. Complementation and Overexpression of CD31
The sequence of human CD31 gR.2 was modified by Q5® Site-Directed Mutagenesis
Kit (NEB #E0554S) in the 20 nucleotide CRISPR region with four silent mutations (high-
lighted in bold) without changing the amino acid sequence (from ATAGCCTCAAAGTCG-
GACAG to ATTGCGTCAAAATCGGATAG). The modified sequences were synthesized
and cloned into pLenti-P2A-GFP-Blast plasmid (modified from pLenti-P2A-Puro, Origene
#PS100109). PLenti-P2A-GFP-Blast with huCD31 with mutated human CD31 gR.2 was used
to generate lentivirus as described above and EA.hy926∆CD31gR.2 and HEK293FT cells
were transduced. After transduction, cells were selected with 6µg/mL and 5 µg/mL blas-
ticidin S hydrochloride (Sigma Aldrich #15205) in EA.hy926 and HEK293FT, respectively.
4.8. CD31 Extracellular Ig Domains Blocking Assay
For the viability assays, EA.hy926 cells were seeded in 96-well plates at a density
of 93,000 cells/cm2 one day before the experiment. The experiment was performed as
previously described [33]. Human CD31 monoclonal antibodies were kindly provided
by Prof. Peter J. Newman, Medical College of Wisconsin, USA. Briefly, cells in each
well were incubated with 100 µL of medium containing 20 µg of one of the following
monoclonal antibodies: CD31-1.2 and 4G6 (CD31 Ig domain 6) and CD31-1.3 (CD31 Ig
domain 1) [41]. Following 60 min incubation at 37 ◦C, cells were washed 2 times with
PBS and incubated with 1 µg/mL CPB for 24 h at 37 ◦C. THP-1 cells (300,000/condition)
were incubated in a medium containing 20 µg of human CD31 mAbs for 60 min. Cells
then were washed twice with PBS and resuspended in medium and were seeded in 96-
well plate in a density of 93,000 cells/cm2 on the same day of the experiment. 1 µg/mL
CPB for 24 h at 37 ◦C were added to the cells. Effects of CPB on cells were measured
using Resazurin assay as mentioned previously. For visualization of cytopathic effects
of EA.hy926, cells were seeded in Nunc® Lab-Tek® chamber slideTM system, in the same
conditions as above and were preincubated with 20 µg of human CD31 mAbs for 1 h, 37 ◦C.
Then, cells were exposed to CPB (1 µg/mL) for 24 h, fixed with methanol and stained with
Eosin/Azur dye (Hemacolor® Rapid staining of blood smear, Merck KGaA). Cytopathic
effects were evaluated by light microscopy with 200× magnification. For SDS-resistant
oligomer formation assay, EA.hy926 were seeded in a density of 40,000/cm2 in T25 and
grown to confluency and 10 million cells of THP-1 cells were used. Cells were incubated
with a medium containing 20 µg of mAbs. Following 60 min incubation at 37 ◦C, SDS-
resistant oligomer formation assay and Western blotting was performed as described above.
All experiments were conducted in two biological replicates.
4.9. Immunofluorescence
Cells grown to confluency on 0.2% gelatin coated glass coverslips were washed with
PBS and subsequently resuspended in ice-cold PBS. All further steps were performed in
a wet chamber. Cells were fixed for 10 min in 4% paraformaldehyde in PBS, pH 7.2 at
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room temperature and washed with ice-cold PBS. Cells were incubated in PBS containing
0.2% Triton X-100 for 10 min and blocked for 45 min with 3% BSA at room temperature.
Cells were rinsed in ice-cold buffer and DNA was stained with Hoechst (ThermoFischer
Scientific) and mounted with Fluorescent Mounting medium (Dako). Images were recorded
with a Nikon Eclipse 80i Fluorescent Microscope.
4.10. Quantification and Statistical Analysis
Statistics were performed using GraphPad Prism 9. Statistical details of experiments
can be found in figure legends. For all multiple comparison two-way ANOVA, Sidak’s
multiple comparison test, a 99.9% confidence interval was used.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/toxins13120893/s1, Figure S1. P2X7 expression in CD31 proficient and deficient cells,
Figure S2. Amino acid sequence of the human CD31 Ig6 domain, Table S1. Amino acid sequence of
recombinant N-terminally His-Tagged CPB.
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